# Omniox

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omniox

- Industry: Pharmaceuticals
- Headquarters: San Carlos, US
- Website: www.omniox.com
- Total disclosed funding: $87M
- Latest round: Series D (Mar 23, 2018)
- Investors on record: 7

## About

Omniox, Inc. is a biotherapeutics company specializing in innovative oxygen delivery technologies designed to improve clinical outcomes for patients suffering from hypoxia-related conditions.Founded in 2006 and headquartered in San Carlos, US, Omniox, Inc. focuses on developing advanced therapies using its proprietary H-NOX platform. The company has engaged in six deals, with its most recent funding round being a Series D in March 2018, where it raised USD 77 mn from various investors including Acadia Woods Partners and Baker Brothers Investments. The CEO and co-founder, Jonathan Winger, has a history of leadership in biotech ventures.Omniox specializes in the development of innovative biotherapeutics through its proprietary H-NOX platform technology, which creates advanced oxygen delivery vehicles known as OMX biologics. These products are engineered to safely deliver oxygen to hypoxic tissues, aiming to restore normal tissue function and improve clinical outcomes. The primary end users are healthcare providers and patients suffering from conditions like cancer and other chronic diseases. Omniox operates mainly in the North American and European markets to address significant unmet medical needs.Omniox's revenue model is structured around B2B transactions, primarily engaging in partnerships with healthcare institutions and pharmaceutical companies. The company licenses OMX biologics for clinical use or participates in joint development programs, often involving milestone payments and royalties based on product sales. Pricing varies depending on collaboration terms, emphasizing the value of its innovative oxygen delivery solutions, ensuring a sustainable revenue stream.Omniox plans to leverage its recent Series D funding of USD 77 mn, raised in March 2018, to support the development of new OMX biologics aimed at enhancing therapeutic applications. The company is also targeting expansion into additional European markets by 2025 to broaden its reach and address new patient populations. This strategic approach will utilize the recent funding to bolster product development and facilitate entry into these new markets.

## Funding rounds

- Series D, Mar 23, 2018, $77M — Emerson, Baker Brothers Advisors, Acadia Woods Partners, Plug and Play, EcoR1 Capital, Samsara BioCapital
- Series C, Jul 26, 2016 — Ariva Partners, Acadia Woods Partners
- Series B, Jun 18, 2014, $6.6M — Ariva Partners, Acadia Woods Partners
- Series A, Aug 6, 2013, $3M — Ariva Partners

## Investors

- Ariva Partners (https://capitalatlas.ai/funds/ariva-partners) — Series A, Series B, Series C
- Acadia Woods Partners (https://capitalatlas.ai/funds/acadia-woods-partners) — Series B, Series C, Series D
- Emerson — Series D
- Baker Brothers Advisors (https://capitalatlas.ai/funds/baker-brothers-advisors) — Series D
- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Series D
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series D
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series D